NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.D., has been appointed Oncology ...
s Head of Oncology Fouad Namouni told Scrip on the sidelines of the 2017 American Society of Clinical Oncology (ASCO) annual meeting, held June 2-6 in ...
Dr. Fouad Namouni, M.D. has been the Head of Oncology Development at Bristol -Myers Squibb Company since July 25, 2016. Dr. Namouni joined Bristol-Myers ...
Sep 12, 2017 ... ... cells, the response rate triples,” said Fouad Namouni, Bristol-Myers' head of ... “ Biomarkers is a major investment field for us,” Namouni said.
Jun 4, 2018 ... The way BMS' oncology development head, Fouad Namouni, sees it, ... biomarker at the time of making treatment decisions,” Namouni said.
Fouad Namouni Head-Oncology Development. Louis S. Schmukler President- Global Manufacturing & Supply. Frederick Egenolf Director-Community Affairs & ...
Sep 18, 2018 ... ... working closely with the EMA as they review this application,” said Fouad Namouni, M.D., head, oncology development, Bristol-Myers Squibb ...
Apr 3, 2017 ... “This level of survival rate at two years is really unprecedented,” said Fouad Namouni, Bristol's head of medical and oncology development.
Dec 21, 2017 ... Fouad Namouni. Yesterday, Taris and BMS announced their collaboration on a Phase Ib combo study for muscle invasive bladder cancer.